Companies / Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

Nasdaq: CGEMCIK 1789972CAMBRIDGE, MA

Financials · FY2022

Revenue$0
Net income$-219.88M
Total debt—
Cash$78.64M
Diluted EPS$-3.69
Shares outstanding64.4M

Ownership

64.4M shares outstanding · as of Jul 31, 2026
1.5%Insiders
Ownership
Insiders1.52%976,084
10%+ / strategic10.54%6,782,759
Institutions91.37%58,802,158
Public float0.00%0

Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 8

View all →
Insider% of sharesShares
Ahmed NadimCEOPresident and CEO · Director
0.61%390,803
Michaelson JenniferChief Scientific Officer
0.27%170,844
Jones Jeffrey AlanChief Medical Officer
0.25%159,968
Sumer Jacquelyn LChief Legal Officer
0.20%128,089
Fenton Mary KayChief Financial Officer
0.20%126,380
Allen Andrew RDirector
——
Savill CorrineChief Business Officer
——
Thistle MaryDirector
——

Institutional holders 159

View all →
HolderValue% of shares
BlackRock, Inc.$95.29M8.13%
Lynx1 Capital Management LP$92.77M13.93%
Bvf INC/IL$81.72M8.94%
MPM BioImpact LLC$79.16M11.88%
State Street Corporation$66.81M5.70%
Vanguard Group Inc$34.14M5.13%
Kynam Capital Management, LP$32.23M4.84%
Blue Owl Capital Holdings LP$24.33M3.65%
Affinity Asset Advisors, LLC$20.00M3.00%
Geode Capital Management, LLC$19.45M2.13%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 20, 2026Ahmed Nadim
CEO
SellCommon Stock$223.1K-16K
-3.89%
404,318
0.63% of shares
medium
Feb 24, 2026Ahmed Nadim
CEO
SellCommon Stock$195.6K-14K
-3.34%
390,803
0.61% of shares
medium
Mar 5, 2026Michaelson Jennifer
Executive
SellCommon Stock$125.4K-8K
-4.47%
170,844
0.27% of shares
medium
Feb 20, 2026Michaelson Jennifer
Executive
SellCommon Stock$114.4K-8K
-4.21%
181,977
0.28% of shares
medium
Feb 20, 2026Jones Jeffrey Alan
Executive
SellCommon Stock$67.9K-5K
-2.94%
164,550
0.26% of shares
low
Feb 24, 2026Jones Jeffrey Alan
Executive
SellCommon Stock$66.3K-5K
-2.78%
159,968
0.25% of shares
low
Feb 20, 2026Fenton Mary Kay
Executive
SellCommon Stock$59.9K-4K
-3.36%
126,380
0.20% of shares
low
Feb 24, 2026Sumer Jacquelyn L
Executive
SellCommon Stock$52.1K-4K
-2.73%
128,089
0.20% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
State Street CorporationPassive13G—3,668,627—
Vanguard Group IncPassive13G/A—0—
Vanguard Group IncPassive13G—3,298,504—
Biotechnology Value Fund L PPassive13G/A———
Kynam Capital Management, LPPassive13G—3,114,132—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
CGEM——230031106—